Menu

Impact of Omicron Subvariants on the Treatment of COVID-19

When:
June 1, 2022 @ 10:50 am – June 1, 2023 @ 11:50 am
2022-06-01T10:50:00+00:00
2023-06-01T11:50:00+00:00

Putting Novel Antibody Therapies for COVID-19 in Clinical Context:
Evaluating Clinical Data, Monitoring, Infusion Best Practices, and Pediatric EUAs

 

View Activity

Impact of Omicron Subvariants on the Treatment of COVID-19

 

PROGRAM FACULTY

Vijaya Soma, MD
Assistant Professor, Pediatrics
Attending Physician, Pediatric Infectious Diseases
NYU Grossman School of Medicine
New York, NY

PROGRAM OVERVIEW

COVID-19 FRONTLINE podcasts provide an up-to-date perspective on the use of monoclonal antibodies for the treatment and prevention of COVID-19. Each podcast focuses on different issues facing clinicians, such as identifying candidates for monoclonal antibody therapy, improving access to therapies, incorporating best practices into clinical care, and other important topics.

In this episode, a pediatric infectious disease specialist will discuss the impact of Omicron subvariants on treatment choices, the use of available vaccines in children, and outcomes of COVID-19 and MIS-C.

TARGET AUDIENCE

The innovative continuing education and tools developed for COVID-19 FRONTLINE will be publicly available for the entire healthcare community to use. This activity is designed to meet the educational needs of health care professionals involved in the care and treatment of pediatric patients with COVID-19, including emergency room physicians, pediatricians, pediatric nurses, NPs, PAs, and pharmacists.

LEARNING OBJECTIVES

On completing this program, attendees should be able to:

  • Recognize challenges in the treatment of patients with COVID-19 and the need for translation of available clinical data into practice
  • Evaluate clinical data and appropriate use considerations with monoclonal antibodies in COVID-19 management, including selection of therapy and dosing in pediatric patients

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the online podcast activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in treating patients with COVID-19.
CNE Credits: 1.0 ANCC Contact Hour.

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 1.0 contact hours of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Dr. Soma has nothing to disclose.

CME Content Review

The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review

The content of this activity was peer reviewed by a nurse reviewer.

Douglas Cox, MSN, MHA, RN
Ultimate Medical Academy/CCM – Lead Nurse Planner

The reviewer of this activity has nothing to disclose.

Staff Planners and Managers

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

  • Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
  • Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
  • Diana Tommasi, PharmD, Medical Director for Med Learning Group, has nothing to disclose.
  • Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
  • Lisa Crenshaw, Senior Program Manager for Med Learning Group, has nothing to disclose.
  • Morgan Kravarik, Associate Program Manager for Med Learning Group, has nothing to disclose.
  • Russie Allen, Accreditation and Outcomes Coordinator, has nothing to disclose.
  • Douglas Cox, MSN, MHA, RN, UMA/CCM – LNP, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and nonapproved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures.
  2. Participate in the enduring activity.
  3. Submit the evaluation form to Med Learning Group.

You will receive your certificate as a downloadable file upon completion.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science-based.
This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making experience before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at [email protected]

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

RELEASE DATE: June 01, 2022

EXPIRATION DATE: June 01, 2023

Copyright © 2022 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

Scroll to Top
Menu

Updates in the Treatment and Prevention of COVID-19​

Molnupiravir, an Oral Antiviral, Reduced the Risk of Hospitalization or Death in Patients with Mild-to-Moderate COVID-19

Molnupiravir, an investigational oral antiviral medicine, significantly reduced the risk of hospitalization or death by 50% in an interim analysis of the phase 3 MOVe-OUT trial. The planned analysis evaluated data from 775 at-risk, non-hospitalized adult patients with mild-to-moderate COVID-19. All patients enrolled had at least one risk factor associated with poor COVID-19 outcomes and were randomized within 5 days of symptom onset. At day 29, 7.3% of patients who received molnupiravir were either hospitalized or died, compared with 14.1% of placebo-treated patients (P= .0012). No deaths were reported in patients receiving molnupiravir, compared with 8 deaths in patients who received placebo. The incidence of any adverse event was comparable in the molnupiravir and placebo groups (35% and 40%, respectively). Discontinuation due to adverse events was lower with molnupiravir (1.3%) versus placebo (3.4%).

Reference:

https://www.contagionlive.com/view/molnupiravir-could-become-first-authorized-covid-19-pill